Cargando…

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

PURPOSE: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed. METHODS: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Epstein, Arthur B, Van Hoven, Peter T, Kaufman, Alan, Carr, Warner W
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709004/ https://www.ncbi.nlm.nih.gov/pubmed/19668586

Ejemplares similares

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
por: Chen, Minjie, et al.
Publicado: (2022)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study
por: Chen, Minjie, et al.
Publicado: (2021)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Comparing the antiplaque efficacy of 0.5% Camellia sinensis extract, 0.05% sodium fluoride, and 0.2% chlorhexidine gluconate mouthwash in children
por: Hambire, Chaitali U., et al.
Publicado: (2015)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Thermoelectric Properties of Ca(3)Co(2−x)Mn(x)O(6) (x = 0.05, 0.2, 0.5, 0.75, and 1)
por: Kanas, Nikola, et al.
Publicado: (2019)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
por: Bhargava, Rahul, et al.
Publicado: (2019)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

The Effects of a High Magnetic Field on the Annealing of [(Fe(0.5)Co(0.5))(0.75)B(0.2)Si(0.05)](96)Nb(4) Bulk Metallic Glass
por: Jia, Peng, et al.
Publicado: (2016)

Analogous Anti-Ferroelectricity in Y(2)O(3)-Coated (Pb(0.92)Sr(0.05)La(0.02))(Zr(0.7)Sn(0.25)Ti(0.05))O(3) Ceramics and Their Energy-Storage Performance
por: Fang, Bijun, et al.
Publicado: (2019)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

Thermoelectric Properties of Ca(1−x)Gd(x)MnO(3−δ) (0.00, 0.02, and 0.05) Systems
por: Bhaskar, Ankam, et al.
Publicado: (2012)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

Giant Negative Electrocaloric Effect in Anti-Ferroelectric (Pb(0.97)La(0.02))(Zr(0.95)Ti(0.05))O(3) Ceramics
por: Zhao, Ying-Cheng, et al.
Publicado: (2019)

High-stability solid solution perovskite (1-x) Bi(0.2)Sr(0.5)La(0.3)TiO(3)- xLaMnO(3) (0.05≤ × ≤0.2) for wide-temperature NTC thermistors
por: Liu, Ting, et al.
Publicado: (2023)

Electrochemical properties of La(0.5)Sr(0.5)Fe(0.95)Mo(0.05)O(3−δ) as cathode materials for IT-SOEC
por: Hou, Yunting, et al.
Publicado: (2021)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

A Primary Dead-Weight Tester for Pressures (0.05–1.0) MPa
por: Jain, Kamlesh, et al.
Publicado: (2003)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%
por: Fidler, Matthew L., et al.
Publicado: (2018)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Electronic, electrical and thermoelectric properties of Ba(0.95)Ca(0.05)Ti(0.95)Y(0.05)O(2.975) compound: Experimental study and DFT-mBJ calculation
por: Saidi, A., et al.
Publicado: (2023)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_70nrfpc7es55iu9hlqch7ahkc5